Cargando…

Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults

Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Alexis R., Sperotto, Francesca, DiNardo, James A., Carlisle, Stephanie, Rivkin, Michael J., Sleeper, Lynn A., Kheir, John N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505337/
https://www.ncbi.nlm.nih.gov/pubmed/34651133
http://dx.doi.org/10.1097/CCE.0000000000000543
_version_ 1784581514717036544
author Cole, Alexis R.
Sperotto, Francesca
DiNardo, James A.
Carlisle, Stephanie
Rivkin, Michael J.
Sleeper, Lynn A.
Kheir, John N.
author_facet Cole, Alexis R.
Sperotto, Francesca
DiNardo, James A.
Carlisle, Stephanie
Rivkin, Michael J.
Sleeper, Lynn A.
Kheir, John N.
author_sort Cole, Alexis R.
collection PubMed
description Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study. DESIGN: Prospective, single-arm study. SETTING: Tertiary care hospital. PATIENTS/SUBJECTS: Eight healthy adult participants. INTERVENTIONS: Subjects underwent hospitalized exposure to 2.4% hydrogen gas in medical air via high-flow nasal cannula (15 L/min) for 24 (n = 2), 48 (n = 2), or 72 (n = 4) hours. MEASUREMENTS AND MAIN RESULTS: Endpoints included vital signs, patient- and nurse-reported signs and symptoms (stratified according to clinical significance), pulmonary function testing, 12-lead electrocardiogram, mini-mental state examinations, neurologic examination, and serologic testing prior to and following exposure. All adverse events were verified by two clinicians external to the study team and an external Data and Safety Monitoring Board. All eight participants (18–30 yr; 50% female; 62% non-Caucasian) completed the study without early termination. No clinically significant adverse events occurred in any patient. Compared with baseline measures, there were no clinically significant changes over time in vital signs, pulmonary function testing results, Mini-Mental State Examination scores, neurologic examination findings, electrocardiogram measurements, or serologic tests for hematologic (except for clinically insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury associated with hydrogen gas inhalation. CONCLUSIONS: Inhalation of 2.4% hydrogen gas does not appear to cause clinically significant adverse effects in healthy adults. Although these data suggest that inhaled hydrogen gas may be well tolerated, future studies need to be powered to further evaluate safety. These data will be foundational to future interventional studies of inhaled hydrogen gas in injury states, including following cardiac arrest.
format Online
Article
Text
id pubmed-8505337
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85053372021-10-13 Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults Cole, Alexis R. Sperotto, Francesca DiNardo, James A. Carlisle, Stephanie Rivkin, Michael J. Sleeper, Lynn A. Kheir, John N. Crit Care Explor Original Clinical Report Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study. DESIGN: Prospective, single-arm study. SETTING: Tertiary care hospital. PATIENTS/SUBJECTS: Eight healthy adult participants. INTERVENTIONS: Subjects underwent hospitalized exposure to 2.4% hydrogen gas in medical air via high-flow nasal cannula (15 L/min) for 24 (n = 2), 48 (n = 2), or 72 (n = 4) hours. MEASUREMENTS AND MAIN RESULTS: Endpoints included vital signs, patient- and nurse-reported signs and symptoms (stratified according to clinical significance), pulmonary function testing, 12-lead electrocardiogram, mini-mental state examinations, neurologic examination, and serologic testing prior to and following exposure. All adverse events were verified by two clinicians external to the study team and an external Data and Safety Monitoring Board. All eight participants (18–30 yr; 50% female; 62% non-Caucasian) completed the study without early termination. No clinically significant adverse events occurred in any patient. Compared with baseline measures, there were no clinically significant changes over time in vital signs, pulmonary function testing results, Mini-Mental State Examination scores, neurologic examination findings, electrocardiogram measurements, or serologic tests for hematologic (except for clinically insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury associated with hydrogen gas inhalation. CONCLUSIONS: Inhalation of 2.4% hydrogen gas does not appear to cause clinically significant adverse effects in healthy adults. Although these data suggest that inhaled hydrogen gas may be well tolerated, future studies need to be powered to further evaluate safety. These data will be foundational to future interventional studies of inhaled hydrogen gas in injury states, including following cardiac arrest. Lippincott Williams & Wilkins 2021-10-08 /pmc/articles/PMC8505337/ /pubmed/34651133 http://dx.doi.org/10.1097/CCE.0000000000000543 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Clinical Report
Cole, Alexis R.
Sperotto, Francesca
DiNardo, James A.
Carlisle, Stephanie
Rivkin, Michael J.
Sleeper, Lynn A.
Kheir, John N.
Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title_full Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title_fullStr Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title_full_unstemmed Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title_short Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults
title_sort safety of prolonged inhalation of hydrogen gas in air in healthy adults
topic Original Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505337/
https://www.ncbi.nlm.nih.gov/pubmed/34651133
http://dx.doi.org/10.1097/CCE.0000000000000543
work_keys_str_mv AT colealexisr safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT sperottofrancesca safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT dinardojamesa safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT carlislestephanie safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT rivkinmichaelj safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT sleeperlynna safetyofprolongedinhalationofhydrogengasinairinhealthyadults
AT kheirjohnn safetyofprolongedinhalationofhydrogengasinairinhealthyadults